For informational and research purposes only. Not medical advice. Content is aggregated from public sources. Always consult a qualified healthcare provider.
Performance & Growth Hormone · Comparison

IGF-1 LR3 vs Melanotan II

A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

IGF-1 LR3Melanotan II
CategoryPerformance & Growth HormonePerformance & Growth Hormone
Also known asInsulin-like Growth Factor-1 Long R3, Long R3 IGF-1, Increlex (human equivalent)MT-II, MTII, Cyclo[Nle4,D-Phe7]-α-MSH
EvidenceResearch-stageResearch-stage
Dosing range20mcg–100mcg mcg, Once daily post-workout, on training days only (common protocol)250mcg–1000mcg mcg, Daily during loading phase; 2–3x weekly for maintenance
AdministrationSubcutaneous injection, Intramuscular injection (into the trained muscle — site-specific protocols)Subcutaneous injection (most common), Intranasal (less effective, lower bioavailability)
Key side effectsHypoglycemia (clinically significant — monitor blood sugar carefully), Jaw and organ growth with chronic high-dose use (theoretical at research doses), Fatigue and headaches, Joint painNausea (most common — especially first 30–60 minutes post-injection), Facial flushing, Spontaneous erections (males — often unwanted at higher doses), Fatigue / yawning post-injection
Cited sources3 references3 references

Key differences

  • Administration: IGF-1 LR3 — Subcutaneous injection, Intramuscular injection (into the trained muscle — site-specific protocols); Melanotan II — Subcutaneous injection (most common), Intranasal (less effective, lower bioavailability).
  • Frequency: IGF-1 LR3 is typically Once daily post-workout, on training days only (common protocol); Melanotan II is Daily during loading phase; 2–3x weekly for maintenance.

How each works

IGF-1 LR3

In vitro and animal research establishes IGF-1 LR3 as a potent anabolic and growth-promoting agent. It activates the IGF-1 receptor (IGF-1R) and downstream PI3K/Akt and MAPK/Erk pathways, promoting skeletal muscle hypertrophy and satellite cell activation. Its extended half-life makes it far more active systemically than native IGF-1. Research also documents its role in connective tissue repair, nerve regeneration, and fat oxidation. Human research is limited — most data comes from cancer cell biology and athletic performance settings.

Melanotan II

Melanotan II's broad melanocortin receptor agonism produces a constellation of effects across multiple systems. MC1R activation in melanocytes upregulates tyrosinase, the rate-limiting enzyme in melanin synthesis, producing UV-independent skin darkening. MC4R activation in the CNS and spinal cord drives sexual arousal and erectogenic effects more potent than most PDE5 inhibitors, and also produces appetite suppression and reduced food intake (the same pathway exploited by weight-loss drugs targeting the melanocortin system). MC3R activation contributes to energy homeostasis effects.

Read the full IGF-1 LR3 profileRead the full Melanotan II profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.